TY - JOUR
T1 - Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus
AU - Vesell, Elliot S.
AU - Chambers, Charles E.
AU - Passananti, G. Thomas
AU - Demers, Laurence M.
AU - Beyer, Karl H.
PY - 1993/9
Y1 - 1993/9
N2 - Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients. 1993 American College of Clinical Pharmacology
AB - Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients. 1993 American College of Clinical Pharmacology
UR - http://www.scopus.com/inward/record.url?scp=0027507732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027507732&partnerID=8YFLogxK
U2 - 10.1002/j.1552-4604.1993.tb01958.x
DO - 10.1002/j.1552-4604.1993.tb01958.x
M3 - Article
C2 - 8227479
AN - SCOPUS:0027507732
VL - 33
SP - 823
EP - 831
JO - Journal of Clinical Pharmacology
JF - Journal of Clinical Pharmacology
SN - 0091-2700
IS - 9
ER -